Stem definition | Drug id | CAS RN |
---|---|---|
antivirals carbocyclic nucleosides | 34 | 136470-78-5 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 77 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1.20 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 29.93 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 83 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.84 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 13 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.50 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 8, 1999 | EMA | ||
Dec. 17, 1998 | FDA | VIIV HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Exposure during pregnancy | 393.92 | 24.46 | 232 | 6900 | 120783 | 50477209 |
Viral mutation identified | 252.27 | 24.46 | 56 | 7076 | 1573 | 50596419 |
Abortion spontaneous | 236.52 | 24.46 | 116 | 7016 | 41656 | 50556336 |
Virologic failure | 227.05 | 24.46 | 51 | 7081 | 1513 | 50596479 |
Hypomania | 218.37 | 24.46 | 61 | 7071 | 4444 | 50593548 |
Jaundice cholestatic | 210.75 | 24.46 | 61 | 7071 | 5050 | 50592942 |
Immune reconstitution inflammatory syndrome | 206.16 | 24.46 | 61 | 7071 | 5455 | 50592537 |
Schizophrenia | 188.52 | 24.46 | 61 | 7071 | 7336 | 50590656 |
Drug resistance | 184.74 | 24.46 | 77 | 7055 | 18912 | 50579080 |
Hepatotoxicity | 173.35 | 24.46 | 82 | 7050 | 27144 | 50570848 |
Pathogen resistance | 153.49 | 24.46 | 49 | 7083 | 5640 | 50592352 |
Lipodystrophy acquired | 132.76 | 24.46 | 32 | 7100 | 1297 | 50596695 |
Psychotic disorder | 130.60 | 24.46 | 63 | 7069 | 21749 | 50576243 |
Blood bilirubin increased | 126.69 | 24.46 | 70 | 7062 | 31968 | 50566024 |
Foetal exposure during pregnancy | 122.73 | 24.46 | 65 | 7067 | 27294 | 50570698 |
Live birth | 118.64 | 24.46 | 54 | 7078 | 16354 | 50581638 |
Premature baby | 106.85 | 24.46 | 52 | 7080 | 18285 | 50579707 |
Cholelithiasis | 97.93 | 24.46 | 63 | 7069 | 37910 | 50560082 |
Stillbirth | 92.79 | 24.46 | 34 | 7098 | 5918 | 50592074 |
Blood HIV RNA increased | 91.20 | 24.46 | 20 | 7112 | 529 | 50597463 |
CD4 lymphocytes decreased | 87.70 | 24.46 | 23 | 7109 | 1316 | 50596676 |
Treatment noncompliance | 85.17 | 24.46 | 53 | 7079 | 30097 | 50567895 |
Abortion induced | 84.50 | 24.46 | 36 | 7096 | 9308 | 50588684 |
Pregnancy | 78.54 | 24.46 | 50 | 7082 | 29527 | 50568465 |
Drug ineffective | 62.85 | 24.46 | 19 | 7113 | 819314 | 49778678 |
Foetal death | 53.11 | 24.46 | 25 | 7107 | 8155 | 50589837 |
Drug reaction with eosinophilia and systemic symptoms | 51.58 | 24.46 | 38 | 7094 | 28386 | 50569606 |
Hepatic enzyme increased | 50.29 | 24.46 | 78 | 7054 | 137302 | 50460690 |
Trisomy 21 | 47.67 | 24.46 | 11 | 7121 | 368 | 50597624 |
Maternal exposure during pregnancy | 45.45 | 24.46 | 81 | 7051 | 159697 | 50438295 |
Infertility | 42.41 | 24.46 | 11 | 7121 | 602 | 50597390 |
Hyperbilirubinaemia | 40.80 | 24.46 | 22 | 7110 | 9548 | 50588444 |
Caesarean section | 40.41 | 24.46 | 26 | 7106 | 15613 | 50582379 |
Ovarian failure | 40.24 | 24.46 | 12 | 7120 | 1099 | 50596893 |
Astrocytoma malignant | 38.89 | 24.46 | 6 | 7126 | 18 | 50597974 |
Placental insufficiency | 38.55 | 24.46 | 12 | 7120 | 1269 | 50596723 |
Vomiting | 38.52 | 24.46 | 147 | 6985 | 460611 | 50137381 |
Fanconi syndrome acquired | 37.95 | 24.46 | 11 | 7121 | 912 | 50597080 |
Premature labour | 37.07 | 24.46 | 22 | 7110 | 11454 | 50586538 |
Pain | 36.67 | 24.46 | 18 | 7114 | 578885 | 50019107 |
Foetal growth restriction | 36.21 | 24.46 | 18 | 7114 | 6609 | 50591383 |
Fall | 36.07 | 24.46 | 3 | 7129 | 334929 | 50263063 |
Pre-eclampsia | 35.72 | 24.46 | 19 | 7113 | 8025 | 50589967 |
Viral load increased | 35.44 | 24.46 | 11 | 7121 | 1152 | 50596840 |
Antiviral drug level below therapeutic | 34.49 | 24.46 | 6 | 7126 | 44 | 50597948 |
Drug interaction | 34.06 | 24.46 | 82 | 7050 | 199539 | 50398453 |
Anaemia | 32.17 | 24.46 | 93 | 7039 | 252363 | 50345629 |
Fatigue | 31.68 | 24.46 | 32 | 7100 | 707569 | 49890423 |
Nephropathy toxic | 30.21 | 24.46 | 17 | 7115 | 8012 | 50589980 |
Central nervous system lesion | 30.15 | 24.46 | 18 | 7114 | 9471 | 50588521 |
Ultrasound scan abnormal | 29.68 | 24.46 | 7 | 7125 | 258 | 50597734 |
Foetal anaemia | 29.61 | 24.46 | 5 | 7127 | 30 | 50597962 |
Oligohydramnios | 29.60 | 24.46 | 15 | 7117 | 5735 | 50592257 |
Isoimmune haemolytic disease | 29.47 | 24.46 | 5 | 7127 | 31 | 50597961 |
Amenorrhoea | 29.34 | 24.46 | 17 | 7115 | 8467 | 50589525 |
HIV infection | 29.19 | 24.46 | 7 | 7125 | 277 | 50597715 |
Pleocytosis | 29.03 | 24.46 | 8 | 7124 | 552 | 50597440 |
Premature delivery | 28.73 | 24.46 | 25 | 7107 | 23638 | 50574354 |
HIV-associated neurocognitive disorder | 28.72 | 24.46 | 6 | 7126 | 125 | 50597867 |
Lipoatrophy | 28.52 | 24.46 | 7 | 7125 | 306 | 50597686 |
Mitochondrial toxicity | 27.58 | 24.46 | 7 | 7125 | 351 | 50597641 |
Proteinuria | 27.45 | 24.46 | 21 | 7111 | 16576 | 50581416 |
Renal tubular dysfunction | 27.30 | 24.46 | 7 | 7125 | 366 | 50597626 |
Generalised anxiety disorder | 26.90 | 24.46 | 10 | 7122 | 1810 | 50596182 |
Social avoidant behaviour | 26.02 | 24.46 | 11 | 7121 | 2786 | 50595206 |
Pubertal failure | 25.69 | 24.46 | 4 | 7128 | 13 | 50597979 |
Paraparesis | 25.67 | 24.46 | 10 | 7122 | 2054 | 50595938 |
HIV wasting syndrome | 25.24 | 24.46 | 4 | 7128 | 15 | 50597977 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lipodystrophy acquired | 540.76 | 15.08 | 151 | 14861 | 2943 | 29556572 |
Immune reconstitution inflammatory syndrome | 492.92 | 15.08 | 175 | 14837 | 7627 | 29551888 |
Mitochondrial toxicity | 368.51 | 15.08 | 106 | 14906 | 2305 | 29557210 |
Virologic failure | 308.57 | 15.08 | 96 | 14916 | 2751 | 29556764 |
Progressive external ophthalmoplegia | 289.34 | 15.08 | 77 | 14935 | 1240 | 29558275 |
Eyelid ptosis | 248.59 | 15.08 | 95 | 14917 | 5091 | 29554424 |
Viral mutation identified | 208.46 | 15.08 | 69 | 14943 | 2419 | 29557096 |
Diplopia | 167.06 | 15.08 | 97 | 14915 | 13421 | 29546094 |
Pathogen resistance | 135.40 | 15.08 | 71 | 14941 | 8045 | 29551470 |
Lipoatrophy | 104.59 | 15.08 | 28 | 14984 | 461 | 29559054 |
Drug resistance | 94.32 | 15.08 | 82 | 14930 | 21458 | 29538057 |
Drug interaction | 84.21 | 15.08 | 255 | 14757 | 197130 | 29362385 |
Blood HIV RNA increased | 84.17 | 15.08 | 28 | 14984 | 996 | 29558519 |
CSF HIV escape syndrome | 81.89 | 15.08 | 19 | 14993 | 167 | 29559348 |
Foetal exposure during pregnancy | 81.39 | 15.08 | 93 | 14919 | 33774 | 29525741 |
Ophthalmoplegia | 77.66 | 15.08 | 30 | 14982 | 1652 | 29557863 |
Polydactyly | 77.36 | 15.08 | 27 | 14985 | 1113 | 29558402 |
HIV-associated neurocognitive disorder | 76.50 | 15.08 | 20 | 14992 | 299 | 29559216 |
Exposure during pregnancy | 74.16 | 15.08 | 49 | 14963 | 8505 | 29551010 |
Dyslipidaemia | 73.54 | 15.08 | 43 | 14969 | 6018 | 29553497 |
Fanconi syndrome acquired | 71.56 | 15.08 | 29 | 14983 | 1813 | 29557702 |
Renal impairment | 65.34 | 15.08 | 134 | 14878 | 81199 | 29478316 |
Hyperlipidaemia | 63.47 | 15.08 | 52 | 14960 | 12538 | 29546977 |
Hypertriglyceridaemia | 62.82 | 15.08 | 42 | 14970 | 7433 | 29552082 |
Osteonecrosis | 60.24 | 15.08 | 52 | 14960 | 13467 | 29546048 |
Off label use | 59.53 | 15.08 | 40 | 14972 | 300760 | 29258755 |
Viral load increased | 58.75 | 15.08 | 26 | 14986 | 2023 | 29557492 |
Kaposi's sarcoma | 56.90 | 15.08 | 20 | 14992 | 842 | 29558673 |
Hyperlactacidaemia | 55.08 | 15.08 | 27 | 14985 | 2651 | 29556864 |
CD4 lymphocytes decreased | 54.76 | 15.08 | 23 | 14989 | 1575 | 29557940 |
Mitochondrial cytopathy | 51.48 | 15.08 | 13 | 14999 | 168 | 29559347 |
Oral candidiasis | 49.31 | 15.08 | 42 | 14970 | 10680 | 29548835 |
Pyrexia | 47.63 | 15.08 | 278 | 14734 | 287344 | 29272171 |
Cachexia | 47.02 | 15.08 | 33 | 14979 | 6316 | 29553199 |
Oesophageal candidiasis | 46.06 | 15.08 | 27 | 14985 | 3794 | 29555721 |
Mitochondrial myopathy | 45.14 | 15.08 | 12 | 15000 | 192 | 29559323 |
Multiple-drug resistance | 42.95 | 15.08 | 26 | 14986 | 3874 | 29555641 |
Blood triglycerides increased | 40.98 | 15.08 | 41 | 14971 | 12793 | 29546722 |
Drug ineffective | 40.51 | 15.08 | 77 | 14935 | 363093 | 29196422 |
HIV infection | 40.47 | 15.08 | 17 | 14995 | 1164 | 29558351 |
Fall | 40.03 | 15.08 | 20 | 14992 | 177158 | 29382357 |
Meningitis cryptococcal | 39.72 | 15.08 | 20 | 14992 | 2080 | 29557435 |
Cytomegalovirus chorioretinitis | 39.35 | 15.08 | 23 | 14989 | 3215 | 29556300 |
Nephrolithiasis | 39.31 | 15.08 | 56 | 14956 | 25278 | 29534237 |
Blood lactic acid increased | 38.18 | 15.08 | 28 | 14984 | 5738 | 29553777 |
Retinal toxicity | 37.04 | 15.08 | 12 | 15000 | 392 | 29559123 |
Acquired immunodeficiency syndrome | 36.39 | 15.08 | 12 | 15000 | 415 | 29559100 |
Lactic acidosis | 35.84 | 15.08 | 59 | 14953 | 30188 | 29529327 |
Fanconi syndrome | 35.54 | 15.08 | 17 | 14995 | 1581 | 29557934 |
Nephropathy toxic | 35.52 | 15.08 | 35 | 14977 | 10721 | 29548794 |
Mycobacterium avium complex infection | 35.42 | 15.08 | 19 | 14993 | 2250 | 29557265 |
White matter lesion | 35.10 | 15.08 | 13 | 14999 | 637 | 29558878 |
Nervous system disorder | 34.19 | 15.08 | 37 | 14975 | 12637 | 29546878 |
Liver disorder | 34.06 | 15.08 | 55 | 14957 | 27694 | 29531821 |
Hepatitis C | 33.22 | 15.08 | 31 | 14981 | 8879 | 29550636 |
Portal hypertension | 32.73 | 15.08 | 21 | 14991 | 3465 | 29556050 |
Completed suicide | 32.11 | 15.08 | 4 | 15008 | 90242 | 29469273 |
HIV associated nephropathy | 32.07 | 15.08 | 10 | 15002 | 288 | 29559227 |
Calculus urinary | 31.06 | 15.08 | 14 | 14998 | 1137 | 29558378 |
Enterovirus infection | 30.99 | 15.08 | 12 | 15000 | 665 | 29558850 |
Trisomy 21 | 30.57 | 15.08 | 11 | 15001 | 496 | 29559019 |
Jaundice | 30.56 | 15.08 | 54 | 14958 | 29242 | 29530273 |
Bone metabolism disorder | 29.59 | 15.08 | 9 | 15003 | 238 | 29559277 |
Bacterial pyelonephritis | 29.41 | 15.08 | 9 | 15003 | 243 | 29559272 |
Genotype drug resistance test positive | 29.39 | 15.08 | 13 | 14999 | 1010 | 29558505 |
Facial wasting | 29.26 | 15.08 | 8 | 15004 | 143 | 29559372 |
Proteinuria | 29.16 | 15.08 | 38 | 14974 | 15766 | 29543749 |
Human immunodeficiency virus transmission | 29.13 | 15.08 | 6 | 15006 | 28 | 29559487 |
Hepatic fibrosis | 29.08 | 15.08 | 19 | 14993 | 3233 | 29556282 |
Atrial fibrillation | 28.63 | 15.08 | 9 | 15003 | 105637 | 29453878 |
Renal tubular disorder | 28.51 | 15.08 | 21 | 14991 | 4331 | 29555184 |
Cerebral toxoplasmosis | 28.30 | 15.08 | 14 | 14998 | 1402 | 29558113 |
Neonatal asphyxia | 28.11 | 15.08 | 9 | 15003 | 283 | 29559232 |
Progressive multifocal leukoencephalopathy | 28.10 | 15.08 | 28 | 14984 | 8691 | 29550824 |
Trimethylaminuria | 27.44 | 15.08 | 5 | 15007 | 10 | 29559505 |
Treatment noncompliance | 27.02 | 15.08 | 46 | 14966 | 24181 | 29535334 |
Transplant rejection | 26.81 | 15.08 | 28 | 14984 | 9184 | 29550331 |
Choroiditis | 26.61 | 15.08 | 12 | 15000 | 976 | 29558539 |
HIV viraemia | 26.36 | 15.08 | 6 | 15006 | 48 | 29559467 |
Gene mutation | 26.01 | 15.08 | 12 | 15000 | 1029 | 29558486 |
Taeniasis | 25.83 | 15.08 | 6 | 15006 | 53 | 29559462 |
Primary syphilis | 25.31 | 15.08 | 5 | 15007 | 18 | 29559497 |
Small for dates baby | 25.11 | 15.08 | 18 | 14994 | 3561 | 29555954 |
Premature baby | 25.06 | 15.08 | 37 | 14975 | 17243 | 29542272 |
Varices oesophageal | 24.81 | 15.08 | 17 | 14995 | 3129 | 29556386 |
Tubulointerstitial nephritis | 24.47 | 15.08 | 37 | 14975 | 17606 | 29541909 |
Pulmonary tuberculosis | 24.25 | 15.08 | 19 | 14993 | 4296 | 29555219 |
Pain | 24.13 | 15.08 | 31 | 14981 | 171401 | 29388114 |
Crystal urine | 24.09 | 15.08 | 6 | 15006 | 73 | 29559442 |
Atrioventricular septal defect | 23.98 | 15.08 | 7 | 15005 | 160 | 29559355 |
Dyspnoea | 23.58 | 15.08 | 86 | 14926 | 326646 | 29232869 |
Blood uric acid increased | 23.31 | 15.08 | 21 | 14991 | 5747 | 29553768 |
Hyperbilirubinaemia | 23.14 | 15.08 | 33 | 14979 | 14901 | 29544614 |
Product dose omission issue | 23.10 | 15.08 | 10 | 15002 | 96373 | 29463142 |
Gamma-glutamyltransferase increased | 22.55 | 15.08 | 45 | 14967 | 26692 | 29532823 |
Blood insulin increased | 22.44 | 15.08 | 8 | 15004 | 351 | 29559164 |
Anogenital warts | 22.31 | 15.08 | 9 | 15003 | 556 | 29558959 |
Lipohypertrophy | 22.14 | 15.08 | 7 | 15005 | 211 | 29559304 |
Loss of anatomical alignment after fracture reduction | 21.96 | 15.08 | 4 | 15008 | 8 | 29559507 |
Subchondral insufficiency fracture | 21.96 | 15.08 | 4 | 15008 | 8 | 29559507 |
Heart transplant rejection | 21.88 | 15.08 | 11 | 15001 | 1140 | 29558375 |
Hepatic function abnormal | 21.83 | 15.08 | 56 | 14956 | 39203 | 29520312 |
Glycosuria | 21.78 | 15.08 | 11 | 15001 | 1151 | 29558364 |
Constipation | 21.42 | 15.08 | 16 | 14996 | 114144 | 29445371 |
Musculoskeletal toxicity | 21.41 | 15.08 | 6 | 15006 | 118 | 29559397 |
Hepatomegaly | 21.37 | 15.08 | 25 | 14987 | 9292 | 29550223 |
Pneumonia | 21.35 | 15.08 | 87 | 14925 | 320085 | 29239430 |
Drug abuse | 21.29 | 15.08 | 7 | 15005 | 79876 | 29479639 |
Coccidioidomycosis | 21.28 | 15.08 | 9 | 15003 | 627 | 29558888 |
Fracture malunion | 21.06 | 15.08 | 4 | 15008 | 11 | 29559504 |
Endocardial fibroelastosis | 20.57 | 15.08 | 4 | 15008 | 13 | 29559502 |
Coronary artery disease | 20.53 | 15.08 | 59 | 14953 | 44131 | 29515384 |
Myocardial infarction | 20.38 | 15.08 | 110 | 14902 | 110186 | 29449329 |
Pancreatic failure | 20.31 | 15.08 | 9 | 15003 | 702 | 29558813 |
Post transplant distal limb syndrome | 20.23 | 15.08 | 7 | 15005 | 281 | 29559234 |
Hypotension | 20.05 | 15.08 | 43 | 14969 | 194311 | 29365204 |
Death | 19.78 | 15.08 | 98 | 14914 | 341986 | 29217529 |
Blood bilirubin increased | 19.53 | 15.08 | 49 | 14963 | 33844 | 29525671 |
Tuberculosis | 19.39 | 15.08 | 21 | 14991 | 7175 | 29552340 |
Brain oedema | 18.93 | 15.08 | 27 | 14985 | 12193 | 29547322 |
Blood pressure increased | 18.75 | 15.08 | 7 | 15005 | 73796 | 29485719 |
Erythema elevatum diutinum | 18.44 | 15.08 | 4 | 15008 | 25 | 29559490 |
Encephalitis | 17.74 | 15.08 | 19 | 14993 | 6411 | 29553104 |
Pancytopenia | 17.47 | 15.08 | 86 | 14926 | 83082 | 29476433 |
Glucose tolerance impaired | 17.23 | 15.08 | 13 | 14999 | 2781 | 29556734 |
Hepatitis A | 17.22 | 15.08 | 7 | 15005 | 441 | 29559074 |
Hepatitis D | 17.15 | 15.08 | 4 | 15008 | 36 | 29559479 |
Skin test negative | 16.96 | 15.08 | 4 | 15008 | 38 | 29559477 |
Ophthalmic herpes simplex | 16.90 | 15.08 | 6 | 15006 | 260 | 29559255 |
Life expectancy shortened | 16.60 | 15.08 | 4 | 15008 | 42 | 29559473 |
Segmented hyalinising vasculitis | 16.51 | 15.08 | 4 | 15008 | 43 | 29559472 |
Congenital pigmentation disorder | 16.47 | 15.08 | 3 | 15009 | 6 | 29559509 |
Pharyngitis | 16.45 | 15.08 | 19 | 14993 | 6964 | 29552551 |
Lymphadenopathy | 16.34 | 15.08 | 38 | 14974 | 25011 | 29534504 |
Dandy-Walker syndrome | 16.17 | 15.08 | 5 | 15007 | 140 | 29559375 |
Hypophosphataemia | 16.11 | 15.08 | 20 | 14992 | 7904 | 29551611 |
Herpes virus infection | 16.10 | 15.08 | 12 | 15000 | 2519 | 29556996 |
Febrile neutropenia | 16.08 | 15.08 | 20 | 14992 | 112220 | 29447295 |
Splenomegaly | 15.85 | 15.08 | 26 | 14986 | 13253 | 29546262 |
Aspartate aminotransferase increased | 15.71 | 15.08 | 66 | 14946 | 59659 | 29499856 |
Malignant neoplasm progression | 15.68 | 15.08 | 9 | 15003 | 73850 | 29485665 |
Induration | 15.57 | 15.08 | 8 | 15004 | 868 | 29558647 |
Fat tissue increased | 15.30 | 15.08 | 6 | 15006 | 344 | 29559171 |
Normal newborn | 15.27 | 15.08 | 5 | 15007 | 169 | 29559346 |
Blood alkaline phosphatase increased | 15.25 | 15.08 | 40 | 14972 | 28366 | 29531149 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Immune reconstitution inflammatory syndrome | 673.18 | 16.24 | 214 | 17700 | 12256 | 64468562 |
Lipodystrophy acquired | 665.88 | 16.24 | 166 | 17748 | 3861 | 64476957 |
Viral mutation identified | 484.16 | 16.24 | 124 | 17790 | 3222 | 64477596 |
Virologic failure | 474.96 | 16.24 | 123 | 17791 | 3343 | 64477475 |
Mitochondrial toxicity | 439.55 | 16.24 | 110 | 17804 | 2596 | 64478222 |
Progressive external ophthalmoplegia | 340.22 | 16.24 | 78 | 17836 | 1249 | 64479569 |
Pathogen resistance | 270.11 | 16.24 | 109 | 17805 | 12434 | 64468384 |
Eyelid ptosis | 248.08 | 16.24 | 95 | 17819 | 9430 | 64471388 |
Drug resistance | 235.26 | 16.24 | 137 | 17777 | 34965 | 64445853 |
Exposure during pregnancy | 203.13 | 16.24 | 170 | 17744 | 77505 | 64403313 |
Abortion spontaneous | 186.85 | 16.24 | 105 | 17809 | 25038 | 64455780 |
Blood HIV RNA increased | 171.36 | 16.24 | 46 | 17868 | 1438 | 64479380 |
Hypomania | 163.90 | 16.24 | 61 | 17853 | 5593 | 64475225 |
Diplopia | 159.82 | 16.24 | 97 | 17817 | 26668 | 64454150 |
Jaundice cholestatic | 138.66 | 16.24 | 61 | 17853 | 8609 | 64472209 |
Schizophrenia | 132.93 | 16.24 | 64 | 17850 | 11104 | 64469714 |
Hepatotoxicity | 120.26 | 16.24 | 95 | 17819 | 39867 | 64440951 |
Drug interaction | 114.46 | 16.24 | 286 | 17628 | 361797 | 64119021 |
CSF HIV escape syndrome | 110.10 | 16.24 | 24 | 17890 | 301 | 64480517 |
Blood bilirubin increased | 108.85 | 16.24 | 105 | 17809 | 57448 | 64423370 |
Lipoatrophy | 108.62 | 16.24 | 27 | 17887 | 618 | 64480200 |
HIV-associated neurocognitive disorder | 93.48 | 16.24 | 21 | 17893 | 305 | 64480513 |
Fanconi syndrome acquired | 92.30 | 16.24 | 32 | 17882 | 2389 | 64478429 |
CD4 lymphocytes decreased | 92.12 | 16.24 | 32 | 17882 | 2403 | 64478415 |
Psychotic disorder | 86.82 | 16.24 | 74 | 17840 | 34504 | 64446314 |
Cholelithiasis | 80.39 | 16.24 | 80 | 17834 | 45426 | 64435392 |
Ophthalmoplegia | 77.75 | 16.24 | 29 | 17885 | 2673 | 64478145 |
Live birth | 73.07 | 16.24 | 43 | 17871 | 11161 | 64469657 |
Hypertriglyceridaemia | 73.07 | 16.24 | 43 | 17871 | 11162 | 64469656 |
Viral load increased | 72.69 | 16.24 | 27 | 17887 | 2460 | 64478358 |
Pain | 70.37 | 16.24 | 33 | 17881 | 553478 | 63927340 |
Dyslipidaemia | 69.72 | 16.24 | 39 | 17875 | 9203 | 64471615 |
Stillbirth | 69.42 | 16.24 | 29 | 17885 | 3604 | 64477214 |
Renal impairment | 69.36 | 16.24 | 130 | 17784 | 134887 | 64345931 |
Abortion induced | 68.21 | 16.24 | 34 | 17880 | 6354 | 64474464 |
Treatment noncompliance | 66.94 | 16.24 | 71 | 17843 | 43411 | 64437407 |
Mitochondrial cytopathy | 63.92 | 16.24 | 16 | 17898 | 377 | 64480441 |
Nephropathy toxic | 62.26 | 16.24 | 46 | 17868 | 17468 | 64463350 |
Fall | 60.91 | 16.24 | 20 | 17894 | 416806 | 64064012 |
Drug ineffective | 59.16 | 16.24 | 89 | 17825 | 840158 | 63640660 |
Hyperlipidaemia | 57.32 | 16.24 | 49 | 17865 | 22927 | 64457891 |
Cachexia | 56.52 | 16.24 | 34 | 17880 | 9183 | 64471635 |
Pyrexia | 56.25 | 16.24 | 304 | 17610 | 558340 | 63922478 |
Off label use | 52.74 | 16.24 | 59 | 17855 | 632747 | 63848071 |
Retinal toxicity | 52.33 | 16.24 | 18 | 17896 | 1312 | 64479506 |
Hepatic enzyme increased | 51.09 | 16.24 | 112 | 17802 | 129831 | 64350987 |
Meningitis cryptococcal | 50.80 | 16.24 | 22 | 17892 | 2987 | 64477831 |
Lactic acidosis | 50.28 | 16.24 | 73 | 17841 | 61337 | 64419481 |
Hyperlactacidaemia | 49.42 | 16.24 | 25 | 17889 | 4819 | 64475999 |
Hyperbilirubinaemia | 48.41 | 16.24 | 43 | 17871 | 21162 | 64459656 |
Mitochondrial myopathy | 48.17 | 16.24 | 12 | 17902 | 277 | 64480541 |
Mycobacterium avium complex infection | 48.15 | 16.24 | 23 | 17891 | 3917 | 64476901 |
Blood lactic acid increased | 47.87 | 16.24 | 32 | 17882 | 10369 | 64470449 |
Drug reaction with eosinophilia and systemic symptoms | 46.66 | 16.24 | 66 | 17848 | 54151 | 64426667 |
Peripheral swelling | 46.29 | 16.24 | 3 | 17911 | 209150 | 64271668 |
Proteinuria | 45.76 | 16.24 | 47 | 17867 | 27676 | 64453142 |
Completed suicide | 44.81 | 16.24 | 5 | 17909 | 224409 | 64256409 |
HIV viraemia | 44.62 | 16.24 | 9 | 17905 | 75 | 64480743 |
Hepatitis C | 43.87 | 16.24 | 31 | 17883 | 10984 | 64469834 |
Osteonecrosis | 43.27 | 16.24 | 46 | 17868 | 28183 | 64452635 |
HIV associated nephropathy | 42.76 | 16.24 | 11 | 17903 | 290 | 64480528 |
Kaposi's sarcoma | 40.97 | 16.24 | 13 | 17901 | 736 | 64480082 |
Multiple-drug resistance | 39.91 | 16.24 | 24 | 17890 | 6478 | 64474340 |
Calculus urinary | 39.48 | 16.24 | 16 | 17898 | 1841 | 64478977 |
Brain oedema | 39.32 | 16.24 | 39 | 17875 | 22036 | 64458782 |
Jaundice | 38.74 | 16.24 | 57 | 17857 | 48455 | 64432363 |
Blood triglycerides increased | 38.65 | 16.24 | 36 | 17878 | 18830 | 64461988 |
Renal tubular disorder | 36.49 | 16.24 | 22 | 17892 | 5965 | 64474853 |
Joint swelling | 35.80 | 16.24 | 8 | 17906 | 215374 | 64265444 |
Cytomegalovirus chorioretinitis | 35.08 | 16.24 | 20 | 17894 | 4892 | 64475926 |
Product dose omission issue | 34.96 | 16.24 | 6 | 17908 | 194741 | 64286077 |
Glycosuria | 34.48 | 16.24 | 15 | 17899 | 2059 | 64478759 |
Foetal death | 34.11 | 16.24 | 21 | 17893 | 5909 | 64474909 |
HIV infection | 33.69 | 16.24 | 12 | 17902 | 970 | 64479848 |
Renal tubular dysfunction | 33.59 | 16.24 | 11 | 17903 | 689 | 64480129 |
Central nervous system lesion | 33.13 | 16.24 | 27 | 17887 | 11822 | 64468996 |
Nephrolithiasis | 32.98 | 16.24 | 50 | 17864 | 43633 | 64437185 |
Pulmonary tuberculosis | 32.65 | 16.24 | 22 | 17892 | 7222 | 64473596 |
Enterovirus infection | 32.51 | 16.24 | 13 | 17901 | 1444 | 64479374 |
Choroiditis | 32.50 | 16.24 | 12 | 17902 | 1075 | 64479743 |
Fanconi syndrome | 31.79 | 16.24 | 15 | 17899 | 2486 | 64478332 |
Renal tubular necrosis | 30.35 | 16.24 | 34 | 17880 | 22076 | 64458742 |
Hepatic fibrosis | 30.27 | 16.24 | 19 | 17895 | 5533 | 64475285 |
Pregnancy | 30.22 | 16.24 | 33 | 17881 | 20832 | 64459986 |
Bone metabolism disorder | 30.00 | 16.24 | 9 | 17905 | 422 | 64480396 |
Sinusitis | 29.76 | 16.24 | 3 | 17911 | 145925 | 64334893 |
Transplant rejection | 29.62 | 16.24 | 30 | 17884 | 17371 | 64463447 |
Taeniasis | 29.44 | 16.24 | 6 | 17908 | 53 | 64480765 |
Genotype drug resistance test positive | 29.29 | 16.24 | 11 | 17903 | 1033 | 64479785 |
Atrial fibrillation | 29.15 | 16.24 | 6 | 17908 | 171083 | 64309735 |
Lymphadenopathy | 29.15 | 16.24 | 49 | 17865 | 46637 | 64434181 |
Pancreatitis | 28.84 | 16.24 | 56 | 17858 | 59551 | 64421267 |
Dyspnoea | 28.72 | 16.24 | 103 | 17811 | 718571 | 63762247 |
Primary syphilis | 28.54 | 16.24 | 5 | 17909 | 17 | 64480801 |
HIV wasting syndrome | 28.41 | 16.24 | 6 | 17908 | 64 | 64480754 |
Oesophageal candidiasis | 28.36 | 16.24 | 21 | 17893 | 7996 | 64472822 |
Portal hypertension | 28.30 | 16.24 | 19 | 17895 | 6200 | 64474618 |
Bacterial pyelonephritis | 27.86 | 16.24 | 9 | 17905 | 540 | 64480278 |
White matter lesion | 27.15 | 16.24 | 12 | 17902 | 1710 | 64479108 |
Constipation | 27.07 | 16.24 | 15 | 17899 | 229322 | 64251496 |
Tuberculosis | 26.94 | 16.24 | 25 | 17889 | 13013 | 64467805 |
Facial wasting | 26.85 | 16.24 | 6 | 17908 | 85 | 64480733 |
Astrocytoma malignant | 26.83 | 16.24 | 5 | 17909 | 26 | 64480792 |
Cerebral toxoplasmosis | 26.48 | 16.24 | 12 | 17902 | 1814 | 64479004 |
Renal failure | 26.28 | 16.24 | 110 | 17804 | 181578 | 64299240 |
Rash maculo-papular | 26.28 | 16.24 | 47 | 17867 | 46979 | 64433839 |
Abdominal discomfort | 26.14 | 16.24 | 9 | 17905 | 182313 | 64298505 |
Encephalitis | 25.77 | 16.24 | 24 | 17890 | 12547 | 64468271 |
Oral candidiasis | 25.73 | 16.24 | 32 | 17882 | 23180 | 64457638 |
Arthralgia | 25.42 | 16.24 | 53 | 17861 | 442207 | 64038611 |
Gamma-glutamyltransferase increased | 25.23 | 16.24 | 47 | 17867 | 48463 | 64432355 |
Coronary artery disease | 24.76 | 16.24 | 53 | 17861 | 60380 | 64420438 |
Swelling | 24.59 | 16.24 | 7 | 17907 | 160211 | 64320607 |
Loss of anatomical alignment after fracture reduction | 24.37 | 16.24 | 4 | 17910 | 8 | 64480810 |
Nasopharyngitis | 24.36 | 16.24 | 12 | 17902 | 196061 | 64284757 |
Nervous system disorder | 24.29 | 16.24 | 31 | 17883 | 23047 | 64457771 |
Ovarian failure | 23.89 | 16.24 | 8 | 17906 | 537 | 64480281 |
Pre-eclampsia | 23.58 | 16.24 | 17 | 17897 | 6214 | 64474604 |
Vomiting | 23.08 | 16.24 | 244 | 17670 | 550873 | 63929945 |
Erythema elevatum diutinum | 22.53 | 16.24 | 4 | 17910 | 15 | 64480803 |
Pubertal failure | 22.53 | 16.24 | 4 | 17910 | 15 | 64480803 |
Blood pressure increased | 22.30 | 16.24 | 10 | 17904 | 172542 | 64308276 |
Aspartate aminotransferase increased | 21.79 | 16.24 | 78 | 17836 | 119710 | 64361108 |
Meningitis tuberculous | 21.67 | 16.24 | 9 | 17905 | 1102 | 64479716 |
Hepatitis | 21.05 | 16.24 | 42 | 17872 | 45540 | 64435278 |
Social avoidant behaviour | 20.92 | 16.24 | 14 | 17900 | 4543 | 64476275 |
Hypophosphataemia | 20.83 | 16.24 | 23 | 17891 | 14697 | 64466121 |
Anogenital warts | 20.78 | 16.24 | 8 | 17906 | 804 | 64480014 |
Alanine aminotransferase increased | 20.74 | 16.24 | 85 | 17829 | 138946 | 64341872 |
Fatigue | 20.57 | 16.24 | 123 | 17791 | 748607 | 63732211 |
Infertility | 20.29 | 16.24 | 7 | 17907 | 515 | 64480303 |
Caesarean section | 20.23 | 16.24 | 20 | 17894 | 11254 | 64469564 |
Breech delivery | 20.21 | 16.24 | 4 | 17910 | 30 | 64480788 |
Post transplant distal limb syndrome | 20.18 | 16.24 | 7 | 17907 | 523 | 64480295 |
CD4 lymphocytes increased | 20.13 | 16.24 | 6 | 17908 | 275 | 64480543 |
Polydipsia | 20.04 | 16.24 | 15 | 17899 | 5806 | 64475012 |
Crystal urine | 19.93 | 16.24 | 5 | 17909 | 119 | 64480699 |
Hepatomegaly | 19.89 | 16.24 | 24 | 17890 | 16858 | 64463960 |
Generalised anxiety disorder | 19.87 | 16.24 | 10 | 17904 | 1905 | 64478913 |
Cushing's syndrome | 19.55 | 16.24 | 8 | 17906 | 943 | 64479875 |
Blood uric acid increased | 19.52 | 16.24 | 17 | 17897 | 8146 | 64472672 |
Ocular icterus | 19.50 | 16.24 | 14 | 17900 | 5084 | 64475734 |
5'nucleotidase increased | 19.49 | 16.24 | 3 | 17911 | 3 | 64480815 |
Hepatic function abnormal | 19.36 | 16.24 | 50 | 17864 | 64263 | 64416555 |
New onset diabetes after transplantation | 19.32 | 16.24 | 5 | 17909 | 135 | 64480683 |
Alopecia | 19.31 | 16.24 | 11 | 17903 | 165679 | 64315139 |
Hepatitis D | 19.27 | 16.24 | 4 | 17910 | 39 | 64480779 |
Myocardial infarction | 19.18 | 16.24 | 94 | 17820 | 165727 | 64315091 |
Antiviral drug level below therapeutic | 19.09 | 16.24 | 4 | 17910 | 41 | 64480777 |
Therapeutic product effect incomplete | 18.98 | 16.24 | 3 | 17911 | 103479 | 64377339 |
Hepatosplenomegaly | 18.91 | 16.24 | 14 | 17900 | 5329 | 64475489 |
Injection site pain | 18.78 | 16.24 | 4 | 17910 | 111404 | 64369414 |
Tubulointerstitial nephritis | 18.70 | 16.24 | 32 | 17882 | 30877 | 64449941 |
Disseminated tuberculosis | 18.69 | 16.24 | 12 | 17902 | 3633 | 64477185 |
Trimethylaminuria | 18.63 | 16.24 | 5 | 17909 | 156 | 64480662 |
Progressive multifocal leukoencephalopathy | 18.42 | 16.24 | 24 | 17890 | 18208 | 64462610 |
Hypercholesterolaemia | 18.35 | 16.24 | 22 | 17892 | 15351 | 64465467 |
Hepatic cirrhosis | 18.30 | 16.24 | 29 | 17885 | 26269 | 64454549 |
Diabetes mellitus | 18.30 | 16.24 | 50 | 17864 | 66424 | 64414394 |
Ear malformation | 18.27 | 16.24 | 3 | 17911 | 6 | 64480812 |
Infected vasculitis | 18.27 | 16.24 | 3 | 17911 | 6 | 64480812 |
Drug abuse | 18.18 | 16.24 | 7 | 17907 | 132367 | 64348451 |
Death | 18.05 | 16.24 | 71 | 17843 | 482634 | 63998184 |
Synovitis | 17.89 | 16.24 | 3 | 17911 | 99087 | 64381731 |
Oligohydramnios | 17.81 | 16.24 | 11 | 17903 | 3113 | 64477705 |
Liver function test abnormal | 17.69 | 16.24 | 46 | 17868 | 59355 | 64421463 |
Pain in extremity | 17.67 | 16.24 | 36 | 17878 | 303049 | 64177769 |
Epistaxis | 17.65 | 16.24 | 3 | 17911 | 98128 | 64382690 |
Subchondral insufficiency fracture | 17.50 | 16.24 | 4 | 17910 | 63 | 64480755 |
Hepatitis A | 17.17 | 16.24 | 7 | 17907 | 817 | 64480001 |
Varices oesophageal | 17.17 | 16.24 | 13 | 17901 | 5117 | 64475701 |
Nephropathy | 17.17 | 16.24 | 16 | 17898 | 8370 | 64472448 |
Fat tissue increased | 17.02 | 16.24 | 7 | 17907 | 836 | 64479982 |
Acute kidney injury | 16.98 | 16.24 | 195 | 17719 | 449045 | 64031773 |
Opportunistic infection | 16.79 | 16.24 | 10 | 17904 | 2652 | 64478166 |
Lower respiratory tract infection | 16.78 | 16.24 | 3 | 17911 | 94611 | 64386207 |
Infection | 16.73 | 16.24 | 16 | 17898 | 184864 | 64295954 |
Liver disorder | 16.60 | 16.24 | 42 | 17872 | 53309 | 64427509 |
Segmented hyalinising vasculitis | 16.46 | 16.24 | 4 | 17910 | 83 | 64480735 |
Chronic kidney disease | 16.38 | 16.24 | 44 | 17870 | 57875 | 64422943 |
Drug level decreased | 16.32 | 16.24 | 18 | 17896 | 11485 | 64469333 |
Hepatitis B | 16.29 | 16.24 | 15 | 17899 | 7730 | 64473088 |
Gene mutation | 16.29 | 16.24 | 9 | 17905 | 2073 | 64478745 |
None
Source | Code | Description |
---|---|---|
ATC | J05AF06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Nucleoside and nucleotide reverse transcriptase inhibitors |
ATC | J05AR02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA MoA | N0000009947 | Nucleoside Reverse Transcriptase Inhibitors |
FDA EPC | N0000175462 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor |
MeSH PA | D019380 | Anti-HIV Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D044966 | Anti-Retroviral Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
FDA MoA | N0000193954 | Cytochrome P450 1A1 Inhibitors |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:53756 | reverse transcriptase inhibitors |
CHEBI has role | CHEBI:88188 | allergenic drug |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Toxic amblyopia | contraindication | 965003 | |
Myositis | contraindication | 26889001 | DOID:633 |
Hepatic failure | contraindication | 59927004 | |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Large liver | contraindication | 80515008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Steatosis of liver | contraindication | 197321007 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Chronic pancreatitis | contraindication | 235494005 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Hypertriglyceridemia | contraindication | 302870006 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Bone marrow depression | contraindication | 307762000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
HLA-B 5701 Positive Status | contraindication | ||
Drug Resistance to Anti-retroviral Therapy | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 13.09 | acidic |
pKa2 | 5.64 | Basic |
pKa3 | 0.88 | Basic |
pKa4 | 0.28 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Reverse transcriptase/RNaseH | Enzyme | INHIBITOR | EC50 | 5.28 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | EC50 | 5.28 | WOMBAT-PK | |||||
Reverse transcriptase | Enzyme | IC50 | 6.89 | CHEMBL |
ID | Source |
---|---|
4029879 | VUID |
N0000180961 | NUI |
D00891 | KEGG_DRUG |
188062-50-2 | SECONDARY_CAS_RN |
168146-84-7 | SECONDARY_CAS_RN |
190521 | RXNORM |
C0663655 | UMLSCUI |
CHEBI:421707 | CHEBI |
1KX | PDB_CHEM_ID |
CHEMBL1380 | ChEMBL_ID |
CHEMBL2106686 | ChEMBL_ID |
CHEMBL4303288 | ChEMBL_ID |
DB01048 | DRUGBANK_ID |
CHEMBL1200619 | ChEMBL_ID |
C106538 | MESH_SUPPLEMENTAL_RECORD_UI |
441300 | PUBCHEM_CID |
11152 | IUPHAR_LIGAND_ID |
7544 | INN_ID |
WR2TIP26VS | UNII |
14010 | MMSL |
191490 | MMSL |
30504 | MMSL |
66957 | MMSL |
7865 | MMSL |
d04376 | MMSL |
007687 | NDDF |
007688 | NDDF |
4021139 | VANDF |
4024130 | VANDF |
4029879 | VANDF |
116084008 | SNOMEDCT_US |
387005008 | SNOMEDCT_US |
412074007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Abacavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0897 | SOLUTION | 20 mg | ORAL | ANDA | 28 sections |
Abacavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-4105 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 28 sections |
Abacavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6523 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 28 sections |
Abacavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-6874 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 28 sections |
Abacavir | Human Prescription Drug Label | 1 | 31722-557 | TABLET | 300 mg | ORAL | ANDA | 27 sections |
Abacavir | Human Prescription Drug Label | 1 | 31722-562 | SOLUTION | 20 mg | ORAL | ANDA | 28 sections |
Abacavir and Lamivudine | Human Prescription Drug Label | 2 | 35573-402 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 29 sections |
Abacavir and Lamivudine | Human Prescription Drug Label | 2 | 35573-430 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 27 sections |
Abacavir and Lamivudine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42291-115 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 28 sections |
EPZICOM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-206 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 27 sections |
EPZICOM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49702-206 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 27 sections |
TRIZIVIR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49702-217 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 26 sections |
TRIZIVIR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49702-217 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 26 sections |
ZIAGEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-221 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 26 sections |
ZIAGEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-221 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 26 sections |
ZIAGEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-222 | SOLUTION | 20 mg | ORAL | NDA | 26 sections |
ZIAGEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-222 | SOLUTION | 20 mg | ORAL | NDA | 26 sections |
Triumeq | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49702-231 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 27 sections |
Triumeq | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49702-231 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 27 sections |
Abacavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-049 | TABLET | 300 mg | ORAL | ANDA | 27 sections |
Abacavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-049 | TABLET | 300 mg | ORAL | ANDA | 27 sections |
Abacavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51079-204 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 29 sections |
Abacavir Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0627 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 30 sections |
EPZICOM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 53808-0767 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 26 sections |
ZIAGEN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0811 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
TRIZIVIR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 53808-0990 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 28 sections |
EPZICOM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5600 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 26 sections |
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | HUMAN PRESCRIPTION DRUG LABEL | 3 | 57297-286 | TABLET | 300 mg | ORAL | ANDA | 29 sections |
Abacavir | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-717 | TABLET | 300 1 | ORAL | ANDA | 25 sections |
Abacavir | Human Prescription Drug Label | 1 | 64980-405 | SOLUTION | 20 mg | ORAL | ANDA | 27 sections |